Evidence map›Paper›PMID 31072360›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

Epithelial CD80 promotes immune surveillance of colonic preneoplastic lesions and its expression is increased by oxidative stress through STAT3 in colon cancer cells.

Chiara Marchiori, Melania Scarpa, Andromachi Kotsafti, Susan Morgan, Matteo Fassan, Vincenza Guzzardo, Andrea Porzionato, Imerio Angriman, Cesare Ruffolo, Stefania Sut and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 43 citations in OpenAlex.

  1. Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Article
  4. Nanoceria as a non-steroidal anti-inflammatory drug for endometriosis theranostics.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Chiara MarchioriDepartment of Molecular Medicine DMM, University of Padua, Padua, Italy.
Melania ScarpaLaboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, via Gattamelata 64, 35128, Padua, Italy. melania.scarpa@iov.veneto.it.ORCID http://orcid.org/0000-0002-7055-635X
Andromachi KotsaftiLaboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, via Gattamelata 64, 35128, Padua, Italy.
Susan MorganPathology Unit, Sheffield Teaching Hospitals, Sheffield, UK.
Matteo FassanSurgical Pathology Unit from the Department of Medicine DIMED, University of Padua, Padua, Italy.
Vincenza GuzzardoSurgical Pathology Unit from the Department of Medicine DIMED, University of Padua, Padua, Italy.
Andrea PorzionatoDepartment of Neurosciences, University of Padua, Padua, Italy.
Imerio AngrimanGeneral Surgery Unit from the Department of Surgery, Oncology and Gastroenterology DISCOG, University of Padua, Padua, Italy.
Cesare RuffoloGeneral Surgery Unit (IV), Ca' Foncello Hospital, Treviso, Italy.
Stefania SutDepartment of Pharmaceutical and Pharmacological Sciences DSF, University of Padua, Padua, Italy.
Stefano Dall'AcquaDepartment of Pharmaceutical and Pharmacological Sciences DSF, University of Padua, Padua, Italy.
Romeo BardiniGeneral Surgery Unit from the Department of Surgery, Oncology and Gastroenterology DISCOG, University of Padua, Padua, Italy.
Raffaele De CaroDepartment of Neurosciences, University of Padua, Padua, Italy.
Carlo CastoroLaboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, via Gattamelata 64, 35128, Padua, Italy.
Marco ScarpaLaboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, via Gattamelata 64, 35128, Padua, Italy.
Ignazio CastagliuoloDepartment of Molecular Medicine DMM, University of Padua, Padua, Italy.
University of Padua · ITIstituto Oncologico Veneto · ITCa' Foncello Hospital · ITSheffield Teaching Hospitals NHS Foundation Trust · GB

Funding

Istituto Oncologico Veneto Fondi di Ricerca CorrenteRegione del Veneto Ricerca finalizzata-progetto MICCE1
6 · The paper itself

Abstract

backgroundOne of the most potent costimulatory molecules involved in the recognition and killing of tumor cells is CD80. However, its role and the molecular mechanisms regulating its expression in sporadic colorectal carcinogenesis remain elusive. Here, we provide evidence for CD80 overexpression in human colon epithelial cells derived from preneoplastic mucosa.

methodsExpression of CD80 on colonic epithelial cells isolated from normal human colonic mucosa, preneoplastic and neoplastic specimens was assessed by flow cytometry. WT and CD80KO mice received azoxymethane to induce colon preneoplastic lesions and sacrificed to perform histology, flow cytometry analysis and immunohistochemistry of colonic mucosa. Some WT mice were treated with a monoclonal anti-CD80 antibody following AOM administration. Primary colon epithelial cells and CT26 cell line were used to quantify the expression of CD80 in response to pro-oxidant stimuli. Specific pharmacological inhibitors and siRNA silencing were used to inhibit MAPK pathways and STAT3.

resultsCD80 expression was significantly increased in colon epithelial cells of human preneoplastic lesions. In the AOM model, CD80 impairment by administration of neutralizing antibodies or use of CD80 knockout mice enhanced dysplasia development. In vitro, CD80 upregulation was induced by oxidative stress in colon cancer cells and primary colon epithelial cells. In addition, reactive oxygen species could induce CD80 expression via the JNK and p38 MAPK pathways, that activated STAT3 transcription factor in colon cancer epithelial cells.

conclusionThis study provide evidence for a major role of CD80 in orchestrating immune surveillance of colon preneoplastic lesions and might help to develop novel approaches that exploit anti-tumor immunity to prevent and control colon cancer.

Indexed as

AnimalsB7-1 AntigenCarcinogenesisColonColonic NeoplasmsEpithelial CellsFlow CytometryGene Expression Regulation, NeoplasticHumansImmunophenotypingIntestinal MucosaMiceMice, KnockoutOxidative Stressp38 Mitogen-Activated Protein KinasesPrecancerous ConditionsB7-1 Antigenp38 Mitogen-Activated Protein KinasesSTAT3 protein, humanSTAT3 Transcription FactorCD80Colorectal cancerDysplasiaImmune surveillance

Identifiers

PMID31072360
PMCPMC6509793
OpenAlexW2947361887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.